ACTRN12618001682235已完成4 期
Investigating the safety and efficacy of chronic administration of Cera-Q on memory and cognitive function in healthy adults.
Bio and Gene0 个研究点目标入组 73 人开始时间: 2018年10月11日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 73
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •People who meet the following inclusion criteria will be included in the trial:
- •1.Male or female, aged 18-70 years, inclusive.
- •2.Willing and able to provide written informed consent.
- •3.Understands and is willing and able to comply with all study procedures.
- •4.Fluent in written and spoken English.
- •5.In good general health as judged by the Investigator/Clinical advisor on the basis of medical history and absence of exclusion criteria
- •6.Normal, or corrected to normal vision.
- •7.Willing to maintain habitual diet (including caffeine and alcohol) and physical activity patterns throughout the study period.
- •8.Willing to abstain from caffeine for 10 hours prior to and throughout the test visits, (up to 6 hours).
- •9.Willing to abstain from alcohol for 24 hours and vigorous physical activity for 12 hours prior to all study visits.
排除标准
- •People who meet the following exclusion criteria will not be included in the trial:
- •1.Current smoker
- •2.History of Type I diabetes (insulin dependent) or Type II diabetes on treatment. (Type II diabetes and prediabetes treated with diet alone is not an exclusion).
- •3.Cardiovascular disease.
- •4.Uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure > 90 mm Hg)
- •5.Neurological conditions including epilepsy, Parkinson’s disease, Myaesthenia Gravis, Huntington’s Chorea.
- •6.History of dementia, stroke and other neurological conditions.
- •7.Head trauma with loss of consciousness in the previous 6 months.
- •8.History of anxiety, depression, or other psychiatric disorders requiring treatment in the last 2 years.
- •9.Current endocrine, gastrointestinal or bleeding disorders.
- •10.Current moderate or severe alcohol misuse disorder as defined in DSM5
- •11.Current substance misuse disorder as defined in DSM5 (including misuse of prescription drugs)
- •12.If female, pregnant or lactating.
- •13.Not willing to abstain from using vitamin E, multivitamins, B vitamin complex, ginkgo biloba, fish oil, St John’s Wort, or other cognitive enhancing dietary or herbal supplements over the study period.
- •14.Taking the following in the 4 weeks preceding the baseline study visit:
- •i.Vitamin supplements including multivitamins, B vitamin complex, vitamin E
- •ii.Herbal supplements including ginkgo biloba, fish oil, St John’s Wort or other cognitive enhancing dietary or herbal supplement
- •iii.Anti-coagulant drugs (warfarin, heparin, clopidogrel, aspirin, dipyrimidole, apixiban , rivaroxiban, dabigatran, tirofiban , ticagrelor);
- •iv.anti-cholinergics or acetylcholinesterase inhibitors (bethanechol (Urecholine), donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl), pyridostigmine (Mestinon)
- •v.anti-depressant medications
- •vi.anti-anxiety medication including benzodiazepines
- •vii.Hypnotics including benzodiazepines, zolpidem and zopiclone
- •15.Participation in any other study involving an investigational product in the preceding 4 weeks.
研究者
相似试验
招募中
3 期
frequent skin ekectrical stimulation for Leber hereditary optic neuropathyeber Hereditary Optic NeuropathyJPRN-jRCTs052200033akamura Makoto15
已完成
不适用
Clinical trial on efficacy and safety of long-term Rebamipide therapy for successful eradication of Helicobacter pylori.Patients who successful eradication therapy of Helicobacter pylori.JPRN-UMIN000002369Department of Internal Medicine, division of Gastroenterology Kawasaki Medical School250
已完成
不适用
A cohort study concerning the efficacy of chronic deep brain stimulation in treatment of back pain in advanced Parkinson's diseases diseaseParkinson's diseaseJPRN-UMIN000005361ihon University, School of Medicine50
进行中（未招募）
不适用
Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosisReduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC.EUCTR2005-002160-28-ATMedical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology80
已完成
不适用
Evaluation of the safety and efficacy of continuous use of skincare formulationsHealthyJPRN-UMIN000039937Beauty & Health Research Inc.46